One thing we know for sure, LGSOC cells are different than high-grade serous ovarian cancer cells. STAAR is extremely grateful to researchers like Drs. Gershenson and Wong, and proud to help fund their research, recently published in Academia Oncology. #LGSOCAwarenessDay #OvarianCancerAwarenessMonth #cancerresearch
STAAR Ovarian Cancer’s Post
More Relevant Posts
-
The results of this multi-center Phase III randomized trial by Steven Frank - MD Anderson Cancer Center American Society of Clinical Oncology (ASCO) #oncodaily #oncology #cancer #research #ASCO24 #ASCO2024
-
Grab a seat and join the conversation as co-host Maria Wilson chats with Louis Vermeulen about the latest breakthroughs in cancer research. They dive into why catching cancer early is so crucial, how personalized treatments are changing outcomes, and the exciting ways #AI and #machinelearning are helping us better diagnose and treat cancer. Our goal is to one day make cancer a condition we can manage long-term. With ongoing research, tailored treatments, and smart use of big data, we’re getting closer each day to making that vision a reality. #TSWIAB
In our latest episode of Two Scientists Walk Into a Bar, cancer researcher Louis Vermeulen discusses the latest advancements in oncology, including new technologies and methods we can leverage to diagnose and treat cancer. Listen to a snippet of his conversation with host Maria Wilson below. http://spr.ly/6043mjbZD
Cancer Conversations: Early Detection and Potent Solutions
-
September marks the start of #OvarianCancerAwarenessMonth, a time to elevate awareness and education – key steps to improving early detection and outcomes. Learn more here: https://lnkd.in/g8enW2i3 Ovarian Cancer Research Alliance #Oncology #OvarianCancer #KnowOvarian
-
-
Thrilled to share that I have successfully completed the Cancer Oncology Online Training Program! This comprehensive course has deepened my understanding and equipped me with the latest insights in oncology. Grateful for this opportunity to advance my knowledge in the fight against cancer. 🩺📚 #Oncology #CancerResearch #ContinuousLearning #ProfessionalDevelopment
-
The TRAIN3 trial of MRI-guided TCHP is out in The Lancet Oncology - Paolo Tarantino https://lnkd.in/gutH_7Kt #oncodaily #oncology #cancer #research #TRAIN3Trial #HER2Positive #BreastCancerResearch #BiomarkerDriven #OncologyInnovation #TheLancetOncology
Paolo Tarantino: The TRAIN3 trial of MRI-guided TCHP is out in The Lancet Oncology - OncoDaily
oncodaily.com
-
From the latest issue of Annals of Surgical Oncology: The Impact of D2 Versus D1 Lymphadenectomy in Siewert II Gastroesophageal Junction (GEJ) Cancer. Read the full article here: https://ow.ly/tvvX50TrYNC
-
-
So fitting for a YIA to be dedicated to him and moving to see such an outpouring of support - Nancy Lin Toni Choueiri Felix Feng American Society of Clinical Oncology (ASCO) Conquer Cancer, the ASCO Foundation https://lnkd.in/dMnfyjVv #ASCO #YIA #BreastOncology #OncoDaily #Oncology
-
-
A very nice overview of the current staples and the new advances in the area of ADCs for breast cancer. Very helpful for increasing comprehension of various BC treatment strategies. Educational note to self: it was interesting to revise that the bystander effect of ADCs plays such a major role in their mechanism of action and that some therapeutic mAbs are specifically engineered to increase this effect, for instance via the intricate designs of the linker fragments or by selection of more membrane-permeable payloads. T-DXd is a fabulous example of such design, a mAb with high drug-antibody ratio and a cleavable linker, proving effective not only in HER2 3+ BC, but also in HER2-low BC by targeting heterogenous tumor cells in addition to the antigen-positive targets. Noting this sent me reading more about ADC design, here are a couple of sources that proved very informative: https://lnkd.in/eeZxrycs https://lnkd.in/eCT9z54h
in this interview, Tanya Gupta, MD, highlighted the approved indications for antibody-drug conjugates in breast cancer, the efficacy data supporting their approvals, and ongoing studies to advance the space further. #BCSM | Stanford University School of Medicine, Stanford Cancer Institute https://lnkd.in/euM-it4a
-
-
Hear from our 7 Travel Grant recipients about their experience at The Tumour Ecosystem' - European Association for Cancer Research (EACR) https://lnkd.in/dKhHhihx #Cancer #CancerResearchers #EACR #OncoDaily #Oncology #TheTumourEcosystem
-
-
Important data from the ENGOT-en11/GOG-3053/KEYNOTE-B21trial - adjuvant pembrolizumab plus in high-risk endometrial cancer. Simultaneous presentation at esmo and publication at annals of oncology #ESMO24
-